|
1
|
Chong CR and Sullivan DJ Jr: New uses for
old drugs. Nature. 448:645–646. 2007. View
Article : Google Scholar : PubMed/NCBI
|
|
2
|
Pantziarka P, Bouche G, Meheus L, Sukhatme
V, Sukhatme VP and Vikas P: The repurposing drugs in oncology
(ReDO) project. Ecancermedicalscience. 8:4422014. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
DiMasi JA, Hansen RW and Grabowski HG: The
price of innovation: New estimates of drug development costs. J
Health Econ. 22:151–185. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Kim J, Tang JY, Gong R, Kim J, Lee JJ,
Clemons KV, Chong CR, Chang KS, Fereshteh M, Gardner D, et al:
Itraconazole, a commonly used antifungal that inhibits Hedgehog
pathway activity and cancer growth. Cancer Cell. 17:388–399. 2010.
View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Navec BA, Grassi P, Dell A, Haslam SM and
Liu JO: The antifungal drug itraconazole inhibits vascular
endothelial growth factor receptor 2 (VEGFR2) glycosylation,
trafficking, and signalling in endothelial cells. J Biol Chem.
286:44045–44056. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Kim DJ, Kim J, Spaunhurst K, Montoya J,
Khodosh R, Chandra K, Fu T, Gilliam A, Molgo M, Beachy PA and Tang
JY: Open-label, exploratory phase II trial of oral itraconazole for
the treatment of basal cell carcinoma. J Clin Oncol. 32:745–751.
2014. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Wang Y, Yao Y, Liu H, Ma X, Lv T, Yuan D,
Xiao X, Yin J and Song Y: Itraconazole can inhibit malignant
pleural effusion by suppressing lymphangiogenesis in mice. Transl
Lung Cancer Res. 4:27–35. 2015.PubMed/NCBI
|
|
8
|
Aftab BT, Dobromilskaya I, Liu JO and
Rudin CM: Itraconazole inhibits angiogenesis and tumor growth in
non-small cell lung cancer. Cancer Res. 71:6764–6772. 2011.
View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Pantziarka P, Sukhatme V, Bouche G, Meheus
L and Sukhatme VP: Repurposing drugs in oncology
(ReDO)-itraconazole as an anti-cancer agent. Ecancermedicalscience.
9:5212015. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Lockhart NR, Waddell JA and Schrock NE:
Itraconazole therapy in a pancreatic adenocarcinoma patient: A case
report. J Oncol Pharm Pract. 22:528–532. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Dirix L: Discovery and exploitation of
novel targets by approved drugs. J Clin Oncol. 32:720–721. 2014.
View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Pace JR, DeBerardinis AM, Sail V,
Tacheva-Grigorova SK, Chan KA, Tran R, Raccuia DS, Wechsler-Reya RJ
and Hadden MK: Repurposing the clinically efficacious antifungal
agent itraconazole as an anticancer chemotherapeutic. J Med Chem.
59:3635–3649. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
You M, Varona-Santos J, Singh S, Robbins
DJ, Savaraj N and Nguyen DM: Targeting the hedgehog signal
transduction pathway suppresses survival of malignant pleural
mesothelioma cells in vitro. J Thorac Cardiovasc Surg. 147:508–516.
2014. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Kast RE, Karpel-Massler G and Halatsch ME:
CUSP9* treatment protocol for recurrent glioblastoma: Aprepitant,
artesunate, auranofin, captopril, celecoxib, disulfiram,
itraconazole, ritonavir, sertraline augmenting continuous low dose
temozolomide. Oncotarget. 5:8052–8082. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Inoue K, Tsubamoto H, Sakata K, Sakane R,
Hao H, Hirota S, Sonoda T and Shibahara H: Expression of hedgehog
signals and growth inhibition by itraconazole in endometrial
cancer. Anticancer Res. 36:149–153. 2016.PubMed/NCBI
|
|
16
|
Kim J, Aftab BT, Tang JY, Kim D, Lee AH,
Rezaee M, Kim J, Chen B, King EM, Borodovsky A, et al: Itraconazole
and arsenic trioxide inhibit Hedgehog pathway activation and tumor
growth associated with acquired resistance to smoothened
antagonists. Cancer Cell. 23:23–34. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Chong CR, Xu J, Lu J, Bhat S, Sullivan DJ
Jr and Liu JO: Inhibition of angiogenesis by the antifungal drug
itraconazole. ACS Chem Biol. 2:263–270. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Rudin CM, Brahmer JR, Juergens RA, Hann
CL, Ettinger DS, Sebree R, Smith R, Aftab BT, Huang P and Liu JO:
Phase 2 study of pemetrexed and itraconazole as second-line therapy
for metastatic nonsquamous non-small cell lung cancer. J Thorac
Oncol. 8:619–623. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Tsubamoto H, Sonoda T, Yamasaki M and
Inoue K: Impact of combination chemotherapy with itraconazole on
survival for patients with recurrent or persistent ovarian clear
cell carcinoma. Anticancer Res. 34:2007–2014. 2014.PubMed/NCBI
|
|
20
|
Takara K, Tanigawara Y, Komada F,
Nishiguchi K, Sakaeda T and Okumura K: Cellular pharmacokinetic
aspects of reversal effect of itraconazole on
P-glycoprotein-mediated resistance of anticancer drugs. Biol Pharm
Bull. 22:1355–1359. 1999. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Gupta A, Unadkat JD and Mao Q:
Interactions of azole antifungal agents with the human breast
cancer resistance protein (BCRP). J Pharm Sci. 96:3226–3235. 2007.
View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Kurosawa M, Okabe M, Hara N, Kawamura K,
Suzuki S, Sakurada K and Asaka M: Reversal effect of itraconazole
on adriamycin and etoposide resistance in human leukemia cells. Ann
Hematol. 72:17–21. 1996. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Tsubamoto H, Sonoda T, Yamasaki M and
Inoue K: Impact of combination chemotherapy with itraconazole on
survival of patients with refractory ovarian cancer. Anticancer
Res. 34:2481–2487. 2014.PubMed/NCBI
|
|
24
|
Antonarakis ES, Heath EI, Smith DC,
Rathkopf D, Blackford AL, Danila DC, King S, Frost A, Ajiboye AS,
Zhao M, et al: Repurposing itraconazole as a treatment for advanced
prostate cancer: A noncomparative randomised phase II trial in men
with metastatic castration-resistant prostate cancer. Oncologist.
18:163–173. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Suzman DL and Antonarakis ES: High-dose
itraconazole as a noncastrating therapy for a patient with
biochemically recurrent prostate cancer. Clin Genitourin Cancer.
12:e51–e53. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Ademuyiwa FO, Zhao Q, Perkins SM,
Gebregziabher N, Jones DR, Vaughn LG, Sledge GW and Miller K: A
pilot trial of itraconazole pharmacokinetics in patients with
metastatic breast cancer. J Clin Oncol. 29:(15 Suppl). e135652011.
View Article : Google Scholar
|
|
27
|
Tsubamoto H, Sonoda T and Inoue K: Impact
of itraconazole on the survival of heavily pre-treated patients
with triple-negative breast cancer. Anticancer Res. 34:3839–3844.
2014.PubMed/NCBI
|
|
28
|
Wahid M, Jawed A, Mandal RK, Dar SA, Khan
S, Akhter N and Haque S: Vismodegib, itraconazole and sonidegib as
hedgehog pathway inhibitors and their relative competencies in the
treatment of basal cell carcinomas. Crit Rev Oncol Hematol.
98:235–241. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Ally MS, Ransohoff K, Sarin K, Atwood SX,
Rezaee M, Bailey-Healy I, Kim J, Beachy PA, Chang AL, Oro A, et al:
Effects of combined treatment with arsenic trioxide and
itraconazole in patients with refractory metastatic basal cell
carcinoma. JAMA Dermatol. 152:452–456. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Tsubamoto H, Sonoda T, Ikuta S, Tani S,
Inoue K and Yamanaka N: Combination chemotherapy with itraconazole
for treating metastatic pancreatic cancer in the second-line or
additional setting. Anticancer Res. 35:4191–4196. 2015.PubMed/NCBI
|
|
31
|
Tsubamoto H, Sonoda T, Ikuta S, Tani S,
Inoue K and Yamanaka N: Impact of itraconazole after first-line
chemotherapy on survival of patients with metastatic biliary tract
cancer. Anticancer Res. 35:4923–4927. 2015.PubMed/NCBI
|
|
32
|
Cooper SM, Sheridan A and Burge S: Mycosis
fungoides responding to systemic itraconazole. J Eur Acad Dermatol
Venereol. 17:588–590. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Vreugdenhil G, Raemaekers JM, van Dijke BJ
and de Pauw BE: Itraconazole and multidrug resistance: Possible
effects on remission rate and disease-free survival in acute
leukaemia. Ann Haematol. 67:107–109. 1993. View Article : Google Scholar
|
|
34
|
Kalderon D: Transducing the hedgehog
signal. Cell. 103:371–374. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
di Pasca Magliano M and Hebrok M: Hedgehog
signalling in cancer formation and maintenance. Nat Rev Cancer.
3:903–911. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Ruiz i Altaba A, Sánchez P and Dahmane N:
Gli and hedgehog in cancer: Tumours, embryos and stem cells. Nat
Rev Cancer. 2:361–372. 2002. View
Article : Google Scholar : PubMed/NCBI
|
|
37
|
Stecca B, Ruiz I and Altaba A:
Context-dependent regulation of the GLI code in cancer by HEDGEHOG
and non-HEDGEHOG signals. J Mol Cell Biol. 2:84–95. 2010.
View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Rimkus TK, Carpenter RL, Qasem S, Chan M
and Lo HW: Targeting the sonic hedgehog signaling pathway: Review
of smoothened and GLI inhibitors. Cancers (Basel). 8:pii: E22.
2016. View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Sekulic A and Von Hoff D: Hedgehog pathway
inhibition. Cell. 164:8312016. View Article : Google Scholar : PubMed/NCBI
|
|
40
|
Sarkar S, Goldgar S, Byler S, Rosenthal S
and Heerboth S: Demethylation and re-expression of epigenetically
silenced tumor suppressor genes: Sensitization of cancer cells by
combination therapy. Epigenomics. 5:87–94. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
41
|
Callaghan R, Luk F and Bebawy M:
Inhibition of the multidrug resistance P-glycoprotein: Time for a
change of strategy? Drug Metab Dispos. 42:623–631. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
42
|
Undevia SD, Gomez-Abuin G and Ratain MJ:
Pharmacokinetic variability of anticancer agents. Nat Rev Cancer.
5:447–458. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
43
|
Itamochi H, Kigawa J, Sultana H, Iba T,
Akeshima R, Kamazawa S, Kanamori Y and Terakawa N: Sensitivity to
anticancer agents and resistance mechanisms in clear cell carcinoma
of the ovary. Jpn J Cancer Res. 93:723–728. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
44
|
Maringe C, Walters S, Butler J, Coleman
MP, Hacker N, Hanna L, Mosgaard BJ, Nordin A, Rosen B, Engholm G,
et al: Stage at diagnosis and ovarian cancer survival: Evidence
from the international cancer benchmarking partnership. Gynecol
Oncol. 127:75–82. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
45
|
Cancer research UK cancer statistics,
ovarian cancer survival statistics. http://www.cancerresearchuk.org/health-professional/cancer-statistics/statistics-by-cancer-type/ovarian-cancer#heading-TwoAccessed.
April;2017.
|
|
46
|
Perez RP, Hamilton TC, Ozols RF and Young
RC: Mechanisms and modulation of resistance to chemotherapy in
ovarian cancer. Cancer. 71:(4 Suppl). S1571–S1580. 1993. View Article : Google Scholar
|
|
47
|
Yoshino K, Enomoto T, Fujita M, Ueda Y and
Kimura T, Kobayashi E, Tsutsui T and Kimura T: Salvage chemotherapy
for recurrent or persistent clear cell carcinoma of the ovary: A
single-institution experience for a series of 20 patients. Int J
Clin Oncol. 18:148–153. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
48
|
Kajiyama H, Shibata K, Mizuno M, Yamamoto
E, Fujiwara S, Umezu T, Suzuki S, Nakanishi T, Nagasaka T and
Kikkawa F: Postrecurrent oncologic outcome of patients with ovarian
clear cell carcinoma. Int J Gynecol Cancer. 22:801–806. 2012.
View Article : Google Scholar : PubMed/NCBI
|
|
49
|
Tsubaoto H, Ito Y, Kanazawa R, Wada R,
Hosoda Y, Honda O, Takeyama R, Sakane R, Wakimoto Y and Shibahara
H: Benefit of palliative chemotherapy and hospice enrolment in
late-stage ovarian cancer patients. J Obstet Gynaecol Res.
40:1399–1406. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
50
|
Tannock IF, de Wit R, Berry WR, Horti J,
Pluzanska A, Chi KN, Oudard S, Théodore C, James ND, Turesson I, et
al: Docetaxel plus prednisone or mitoxantrone plus prednisone for
advanced prostate cancer. N Engl J Med. 351:1502–1512. 2004.
View Article : Google Scholar : PubMed/NCBI
|
|
51
|
Brufsky A, Valero V, Tiangco B, Dakhil S,
Brize A, Rugo HS, Rivera R, Duenne A, Bousfoul N and Yardley DA:
Second-line bevacizumab-containing therapy in patients with
triple-negative breast cancer: Subgroup analysis of the RIBBON-2
trial. Breast Cancer Res Treat. 133:1067–1075. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
52
|
Staudacher L, Cottu PH, Diéras V,
Vincent-Salomon A, Guilhaume MN, Escalup L, Dorval T, Beuzeboc P,
Mignot L and Pierga JY: Platinum-based chemotherapy in metastatic
triple-negative breast cancer: The institut curie experience. Ann
Oncol. 22:848–856. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
53
|
Liu M, Mo QG, Wei CY, Qin QH, Huang Z and
He J: Platinum-based chemotherapy in triple-negative breast cancer:
A meta-analysis. Oncol Lett. 5:983–991. 2013.PubMed/NCBI
|
|
54
|
American cancer society, . cancer facts
and figures 201s. 2016 https://www.cancer.org/acs/groups/content/@research/documents/document/acspc-047079.pdfAccessed.
April;2017.
|
|
55
|
Miller DL and Weinstock MA: Nonmelanoma
skin cancer in the United States: Incidence. J Am Acad Dermatol.
30:774–778. 1994. View Article : Google Scholar : PubMed/NCBI
|
|
56
|
Sekulic A, Migden MR, Oro AE, Dirix L,
Lewis KD, Hainsworth JD, Solomon JA, Yoo S, Arron ST, Friedlander
PA, et al: Efficacy and safety of vismodegib in advanced basal-cell
carcinoma. N Engl J Med. 366:2171–2179. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
57
|
Pivotal data for Novartis' investigational
compound LDE225 show marked tumor responses in advanced basal cell
carcinoma. 2014 http://www.oncotrends.de/pivotal-data-for-novartis-investigational-compound-lde225-sonidegib-show-marked-tumor-responses-in-advanced-basal-cell-carcinoma-422202Accessed.
April;2017.
|
|
58
|
Migden MR, Guminski AD, Gutzmer R, Dirix
LY, Lewis KD, Combemale P, Herd R, Gogov S, Yi T, Mone M, et al:
Randomized, double-blind study of sonidegib (LDE225) in patients
(pts) with locally advanced (La) or metastatic basal-cell carcinoma
(BCC). J Clin Oncol. 32:5s2014.
|
|
59
|
Rahma OE, Duffy A, Liewehr DJ, Steinberg
SM and Greten TF: Second-line treatment in advanced pancreatic
cancer: A comprehensive analysis of published clinical trials. Ann
Oncol. 24:1972–1979. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
60
|
Patel T: Increasing incidence and
mortality of primary intrahepatic cholangiocarcinoma in the United
States. Hepatology. 33:1353–1357. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
61
|
Lamarca A, Hubner RA, David Ryder W and
Valle JW: Second-line chemotherapy in advanced biliary cancer: A
systematic review. Ann Oncol. 25:2328–2338. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
62
|
Vreugdenhil G, Van Dijke BJ, Donnelly JP,
Novakova IR, Raemaekers JM, Hoogkamp-Korstanje MA, Koster M and de
Pauw BE: Efficacy of itraconazole in the prevention of fungal
infections among neutropenic patients with hematologic malignancies
and intensive chemotherapy. A double blind, placebo controlled
study. Leuk Lymphoma. 11:353–358. 1993. View Article : Google Scholar : PubMed/NCBI
|
|
63
|
Gupta S, Kim J and Gollapudi S: Reversal
of daunorubicin resistance in P388/ADR cells by itraconazole. J
Clin Invest. 87:1467–1469. 1991. View Article : Google Scholar : PubMed/NCBI
|
